Shares of Hikma Pharmaceuticals Plc (HIK.L, HKMPY.PK) declined around 5percent in the morning trading in London after the company announced Friday that it received a Warning Letter from the U.S. Food and Drug Administration or FDA on Thursday related to the inspection of its manufacturing facility in Portugal in March 2014.
In the letter, the agency raised issues related to investigations and environmental monitoring at the facility.
Hikma said it takes this matter very seriously and will work with the FDA to fully resolve all outstanding issues.
The company further said that at this point, it does not anticipate that the warning letter will impact the manufacturing or distribution of the products manufactured in its Portugal facility. The company also does not expect this to impact its financial guidance for 2014.
Hikma said it will provide further updates in due course, while noting that it remains committed to the highest standards of quality and compliance across its 27 manufacturing facilities in 11 countries.
In London, Hikma shares were losing 91 pence or 4.79 percent, and trading at 1,809 pence.
For comments and feedback contact: editorial@rttnews.com